Member Info for Schomosport

Update, AJBell corporate actions message
Following the Scheme of Arrangement, shares have now been removed from CREST. Holdings have been moved to certficated pending receipt of certificates which will then be deposited with our overseas custodian to enable trading.
Updated: 09/11/2021

Progress of sorts.........

Update. AJBell dealing team chasing corporate actions for update re: TLSA, ACCUSTEM

So no news but knowing I have something logged within AJBell that I can point to sits abit easier with me if nothing else.

Update:
3 corporate messages received to day via AJBell. Summarised:
Scheme of arrangement
Court meeting to approve.
At some date defined at court meeting (subject to approval) ACCUSTEM list on NASDAQ at 20:1 consolidation
Because of the 'can't hold on CREST', 'US custodian' situation (all detailed in the corporate actions, so I am not going to repeat it verbatim here), UK holders entitld to Accustem shares will receive their 20:1 entitlement up to 14 days later.

Very similar to TILS move from LSE to NASDAQ - that said, more than 14 days have passed since 18th October which was the date in the TILS corprate action (from memory) and still no NASDAQ:TLSA credited to my account. Chased AJBell about this yesterday, still waiting for a response. Cheers all.

As a newbie (24 months) trader I sit in front of the screen for a good part of the day and I look at the share price charts of dozens of shares not to mention the 30 odd I have money in. What is happening here is nothing unusual for an AIM share that has promised a lot, not delivered all that it has promised, and is ominously quite regarding news flow. Two equal parallels in pharma, both of which I hold well under water, are #TILS and #DDDD. The first ramped to death over a dividend in specie and all sorts of NASDAQ shenanigans, the second with a million or two world changing patents, few of which have yet produced any meaningful money. Go and look at the charts and then tell me the difference at a high level between them and ORPH. Then tell me I sure know how to put my money into losers (smile). I could point you to many other shares, especially on AIM, which have exhibited similar trends since April.

Just commentary for the disillusioned who may only monitor ORPH and nothing else. ORPH is my largest position and, at 25% of my porfolio, doesn't win me any prizes for risk management. I shall continue to hold. Fortunately I have a low average at 14p but by gosh, that was an aweful lot of profit I left unbanked, I curse my error daily. ATB

Sent the following to AJBell this morning. Will update as and when I receive a response. I have received no corporate action or secure messages from AJBell on this topic, only thanbks to this BB do I even know about the Scheme of Arrangement, consolidation, etc.

Message:

RNS Number : 1070R
Accustem Sciences Limited
02 November 2021

Sets out the scheme of arrangement whereby uncertificated shares held in CREST for ACCUSTEM SCIENCES ORD GBP0.01 will be cancelled after which they are expected to be relisted on NASDAQ in 2022.
https://www.londonstockexchange.com/news-article/market-news/scheme-of-arrangement/15197179

The scheme document referenced from the scheme of arrangement is available at
http://www.accustem.com/assets/accustem-scheme-document.pdf

It contains the following at II part 10:

10.2 UK Accustem Shares held in uncertificated form (i.e. in CREST)
UK Accustem Shares held in uncertificated form will be disabled in CREST on the Scheme
Effective Date.
Unlike UK Accustem Shares, US Accustem Shares are not capable of being held, transferred
or settled directly through the CREST settlement system. A Scheme Shareholder who holds
Scheme Shares in uncertificated form through CREST (directly or through a broker or other
nominee with a CREST account) immediately prior to the Scheme Record Time will be issued
US Accustem Shares in the manner described below.
As soon as practicable and, in any event, no later than 14 days after the Scheme Effective
Date, PST will mail a statement by first class mail to each Scheme Shareholder holding Scheme
Shares in uncertificated form providing evidence of ownership of the US Accustem Shares such
Scheme Shareholder holds. Such Scheme Shareholders wishing to deposit their US Accustem
Shares electronically with DTC will need to contact their brokers to arrange for deposit of those
shares following receipt of their statement providing evidence of ownership. Temporary
documents of title will not be issued and transfer of US Accustem Shares by such Scheme
Shareholders will not be permitted until they receive their statement providing evidence of
ownership and effect such transfer in accordance with the directions on such statement.
Accordingly, holders of Scheme Shares in uncertificated form should be aware that there
will be a delay in their ability to deal with their US Accustem Shares until after they
receive their statement providing evidence of ownership.

Can you please tell me how this will work in practice so that my existing ACCUSTEM SCIENCES ORD GBP0.01 become NASDAQ:ACCUSTEM (or whatever the ticker will be) given that the quoted text above makes reference to hard copy evidence of entitlement.

The scheme document also makes reference to a 20:1 share consolidation. - Page 10, part 3 - "The exchange ratio is on a twenty-for-one basis"

Thank you.

Possibly old news but from the horse's mouth this morning:

The new Tiziana shares will be available for trading online through our
platform once these have listed on the NASDAQ. You should be able to trade these at the standard online rate, however, as they will be
listed in the US trading in USD then you will incur FX charges when coming to trade the investment. Our FX charges are as follows:

1% for 1st 10,000GBP
0.75% for 2nd 10,000GBP
0.5% for 3rd 10,000GBP
0.25% for 30,000GBP+

People don't post to be ignored. I have no issues with reasoned opposing views, and even less time for unbalanced fanboys who only want their confirmation bias to be reinforced. However, if you persist in responding to someone who has submitted 40 odd negative posts you have only yourselves to blame if you keep responding to him.
For the record #ORPH is my biggest holding .

Yes. The NASDAQ listing is still a WIP. God knows why but it is. Just be thankful they now exist as a placeholder giving some small evidence to your entitlement, that in itself is several weeks late. Mine also with YouInvest.
Whether or not they will ever be worth anything another Q entirely.

Also quote from RNS where they are claiming about 1/2 liabilities are not due in 12m

At 30 June 2021, the Group had a working capital deficit of $7.6 million, however the Directors have considered the circumstances, current status and practical realisations of $11.7 million of current liabilities that relate to long-term historic liabilities and based on this assessment do not believe that these will become due in the going concern period under review

AIM Immunotech (the customer)
Market Cap 96.6m (USD)
Turnover 0.2m
Profit -14.4m
Cash 38.5m
Don't know idea what the contract value is, at least they appear to have the cash to pay the bill.

The converse answer for those lamenting the drop in price and absence of news from CF is that despite the errosion of value he is chilled. The price will find its bottom when there are as many believers as doubters. Sticking some bland 'steady as she goes' notice out will only stall the fall for a few days before, in the continued absence of news, it continues to fall. Down about 9% in the value of my pf since April attributable to ORPH, I Continue to believe and hold, though not sure when we will see 45p again.

Top 50 at https://twitter.com/neverton_29/status/1412371656715218945?s=20

Anyone seen hard copy of the question & answer session on 17th June? Still showing as pending on the InvestorMeetCompany site. Can't locate it on the OO site.

So what other inside information are you ready to declare on a public BB?

Regarding mud slinging and rattled PIs. A fanboy bb is of no use to anyone other than those who want only views that confirm their bias. intelligent debate and alternative points of view that challenge cherished beliefs is healthy and should be welcomed.

My biggest holding however for a final results presentation very disappointing for content and management. Almost 20 minutes intro covering old ground before getting to results. Lost count of number of times I heard in-species div would be tax free. No searching questions on accounts contents. Numerous very basic questions from people with little or no understanding of ex-dividend dates. Touted to be a billion dollar enterprise in the making and people are asking really basic questions of a CEO that they should know the answers to. IMC needs an experienced hand to compere the proceedings, keep the presenters from repeating themselves and filter out basic and repeated questions. This was a dog and pony show and a missed opportunity to present the company in the best light.

475,000 trade marked as sell at 108p just after close. Interesting!

Markets can stay irrational longer than you can stay solvent.

September 7th dropped 20% and immediately recovered
January 19th fell 9 days until down 20% then recovered
March 11th started current decline now down 20%

PM basket remains strong albeit gold getting hammered which may have beld across to less informed holders. Story remains good and strong, increased holding just now by 50% at 105.5. I had enough already so probbaly flip the latest addition for a few pence as II am keen to stay liquid in these markets.

I have acounts with both AJ Bell and HL. HL are equally culpable regarding freezing up when times are busy, I have also heard some horor stories where they cannot even keep reliable records of portfolio contents. Hasn't happened to me so far but it does often take 10s of seconds to update after a trade so that you are not entirely confident if it has been actioned or not.

So do I. Below from Peel Hunt courtesy of Philanderer you know where. I continue to watch with interest.

Peel Hunt eyes Marston’s recovery Pub and brewery group Marston’s (MARS) has a ‘roadmap’ for the future and Peel Hunt says there is scope for a ‘re-rating. Analyst Douglas Jack retained his ‘buy’ recommendation and target price of 95p on the shares, which fell 6% to 65.8p yesterday after posting an almost £400m annual loss. ‘Marston’s has a clear roadmap to debt reduction and resumed dividends with minimal disposal activity,’ said Jack. ‘Its investment in apps, shorter menus and outdoor areas have contributed to an 11% increase in guest satisfaction scores. This should all pay dividends as the sector recovers.’ Jack added that with debt reduction forecasts to continue and the vaccine roll out accelerating ‘there is scope for the shares to continue to re-rate’. HTTPS://citywire.co.uk/funds-insider/news/the-expert-view-workspace-firstgroup-and-spectris/a1437266?section=funds-insider&_ga=2.181610151.1687547678.1607685024-1419783115.1607685024#i=6